Ccl2 Polymorphism As A Predictive Marker For Bevacizumab (Bev) Hi Combination With Folfiri As First-Line Treatment In Metastatic Colorectal Cancer (Mcrc) Patients (Pts)

e14556 Background: CCL2 is a chemokine which plays a central role in immunosurveillance in the tumor microenvironment. The CCL2 also controls the recruitment of leukocytes to tissues during inflammation and has a number of tumor-promoting activities. Importantly, the CCL2 promotes the polarization into M2 macrophages which play immunosuppressive roles and secrete angiogenic factors such as vascular endothelial growth factor (VEGF). We hypothesized that single nucleotide polymorphism (SNP) in CCL2 may predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with anti-VEGF drug in combination with chemotherapy. Methods: Genomic DNA was extracted from blood of 424 mCRC pts treated with FOLFIRI plus bevacizumab (Bev) as first-line treatment and prospectively enrolled in a prospective pharmacogenomics translational study in Italy. Median follow-up time was 2.8 (range: 0.7-6.0) years, median progression-free survival (PFS) and overall survival (OS) were 10.4 (range: 9.8-10.9) and 2...